DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for asphyxia neonatorum — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAsphyxia neonatorum maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for asphyxia neonatorum is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 5A (PDE5A) — PDE5A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-methyl-7-oxo-3-propyl-6,7-dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3BJC · 2.0 Å · ligand 5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide (WAN). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Pediatrics and Adolescent Medicine · 1934 · 18 citations
PATHOGENESIS OF ATELECTASIS OF THE NEW-BORN
Abstract<i>To the Editor</i>:—In a recent paper on "Pathogenesis of Atelectasis of the New-Born" in theAmerican Journal of Diseases of Children(<b>46</b>:590 [Sept.] 1933) by J. L. Wilson and Sidney Farber, a conception of asphyxia neonatorum is imputed to me which is widely different from that which I actually hold (Fundamentals of Asphyxia,<i>J. A. M. A.</i><b>101</b>:261 [July 22] 1933). Even in the earlier paper quoted by Farber and Wilson, in which they represent me as stating that in asphyxia the respiratory "stimulus is not present" or "abnormally low," it was stated that the respiratory center is "depressed by asphyxia" (lack of oxygen) and that "more than the normal stimulus (of carbon dioxide) is required to induce breathing."
Analysing in the association factors of asphyxia neonatorum and nursing on it's resuscitation
AbstractObjective To evaluate the associated factors of asphyxia neonatorum and it's resuscitation principle and nursing provision.Methods we retrospectively analyzed the clinical data of 180 cases of asphyxia neonatorum.Results All of the abnormality of umbilical cord,delay of stage of labor,premature labor and premature repture of fetal membranes were the common factor lead to asphyxia neonatorum.Conclusions To strenghen monitoring in the stage of labor,to treat the morbidity of fatal distress in time,and to choose the natal mode truly.We can prevent and low the asphyxia neonatorum effective.
Key words:
Asphyxia neonatorunm; Analyse; Resuscitation; Nursing
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
